Patents by Inventor Jeffrey T. Vicenzi

Jeffrey T. Vicenzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6160133
    Abstract: A process for stereoselectively forming N-substituted dihydro-2,3 benzodiazepines which are useful as AMPA receptor antagonists. The process includes an opening reduction step which sets the stereochemistry of the intermediates and the final compounds to the desired enantiomer. The reduction step may be carried out by an enzymatic reduction.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: December 12, 2000
    Assignee: Eli Lilly and Company
    Inventors: David L. Varie, Jeffrey T. Vicenzi, Milton J. Zmijewski
  • Patent number: 5919954
    Abstract: A process for stereoselectively forming N-substituted dihydro-2,3 benzodiazepines which are useful as AMPA receptor antagonists. The process includes an opening reduction step which sets the stereochemistry of the intermediates and the final compounds to the desired enantiomer. The reduction step may be carried out by an enzymatic reduction.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Benjamin A. Anderson, Marvin M. Hansen, David L. Varie, Jeffrey T. Vicenzi, Milton J. Zmijewski
  • Patent number: 5665878
    Abstract: A process for stereoselectively forming N-substituted dihydro-2,3 benzodiazepines which are useful as AMPA receptor antagonists. The process includes an opening reduction step which sets the stereochemistry of the intermediates and the final compounds to the desired enantiomer. The reduction step may be carried out by an enzymatic reduction.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: September 9, 1997
    Assignee: Eli Lilly and Company
    Inventors: Benjamin A. Anderson, Marvin M. Hansen, David L. Varie, Jeffrey T. Vicenzi, Milton J. Zmijewski
  • Patent number: 5559006
    Abstract: "A method for selectively deactivating catalase while retaining D-amino acid oxidase activity is disclosed. The catalase and oxidase are both present in whole cells or a cell-free extract. The method comprises combining the whole cells or the cell-free extract with a basic solution at a pH between about 11 and about 12. The catalase activity is eliminated and the oxidase activity is unaffected. This results in the production of a solution which contains oxidase activity but no catalase activity. The whole cells and cell-free extract are preferably from Triginopsis variabilis.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: September 24, 1996
    Assignee: Eli Lilly and Company
    Inventor: Jeffrey T. Vicenzi
  • Patent number: 5424203
    Abstract: A method for selectively deactivating catalase while retaining D-amino acid oxidase activity is disclosed. The catalase and the oxidase are both present in whole cells or a cell-free extract. The method comprises combining the whole cells or the cell-free extract with a basic solution at a pH between about 11 and about 12 for a time of about 1 hour and 45 minutes to about 2 hours. The catalase activity is eliminated and the oxidase activity is uneffected. This results in the production of a solution which contains the oxidase and which has no catalase activity. The pH of the solution containing the oxidase is then lowered to provide a D-amino acid oxidase capable of enzymatic oxidation of cephalosporin C to glutaryl-7-ACA in high yields. The whole cells and cell-free extract are preferrably from Triginopsis variablilis.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: June 13, 1995
    Assignee: Eli Lilly and Company
    Inventor: Jeffrey T. Vicenzi
  • Patent number: 4921947
    Abstract: This invention provides an improvement in the process for preparing C-20-amino-substituted derivatives of the macrolide antibiotics of the tylosin type by reductively aminating the C-20 aldehyde group in the parent antibiotic. The improvement comprises using formic acid as the reducing agent. The new process is less expensive and more amenable to scale-up than previously used processes, but is still selective.
    Type: Grant
    Filed: March 31, 1986
    Date of Patent: May 1, 1990
    Assignee: Eli Lilly and Company
    Inventors: Eddie V. P. Tao, Jeffrey T. Vicenzi